Egr-1 inhibits the expression of extracellular matrix genes in chondrocytes by TNFα-induced MEK/ERK signalling
© Rockel et al.; licensee BioMed Central Ltd. 2009
Received: 10 November 2008
Accepted: 14 January 2009
Published: 14 January 2009
TNFα is increased in the synovial fluid of patients with rheumatoid arthritis and osteoarthritis. TNFα activates mitogen-activated kinase kinase (MEK)/extracellular regulated kinase (ERK) in chondrocytes; however, the overall functional relevance of MEK/ERK to TNFα-regulated gene expression in chondrocytes is unknown.
Chondrocytes were treated with TNFα with or without the MEK1/2 inhibitor U0126 for 24 hours. Microarray analysis and real-time PCR analyses were used to identify genes regulated by TNFα in a MEK1/2-dependent fashion. Promoter/reporter, immunoblot, and electrophoretic mobility shift assays were used to identify transcription factors whose activity in response to TNFα was MEK1/2 dependent. Decoy oligodeoxynucleotides bearing consensus transcription factor binding sites were introduced into chondrocytes to determine the functionality of our results.
Approximately 20% of the genes regulated by TNFα in chondrocytes were sensitive to U0126. Transcript regulation of the cartilage-selective matrix genes Col2a1, Agc1 and Hapln1, and of the matrix metalloproteinase genes Mmp-12 and Mmp-9, were U0126 sensitive – whereas regulation of the inflammatory gene macrophage Csf-1 was U0126 insensitive. TNFα-induced regulation of Sox9 and NFκB activity was also U0126 insensitive. Conversely, TNFα-increased early growth response 1 (Egr-1) DNA binding was U0126 sensitive. Transfection of chondrocytes with cognate Egr-1 oligodeoxynucleotides attenuated the ability of TNFα to suppress Col2a1, Agc1 or Hapln1 mRNA expression.
Our results suggest that MEK/ERK and Egr1 are required for TNFα-regulated catabolic and anabolic genes of the cartilage extracellular matrix, and hence may represent potential targets for drug intervention in osteoarthritis or rheumatoid arthritis.
Chondrocytes maintain articular cartilage through coordinated production and degradation of the extracellular matrix. Type II collagen, aggrecan, and link protein – encoded by the genes Col2a1, Agc1 and Hapln1, respectively – are major components of the articular cartilage extracellular matrix (ECM). Type II collagen is the major structural collagen of articular cartilage . Aggrecan is the most abundant proteoglycan, and is responsible for resisting the compressive forces imposed on articulating joints . Finally, link protein stabilizes the association of aggrecan with hyaluronic acid . The expression of these ECM proteins is regulated by transcription factors within the nucleus promoting or inhibiting transcript production. Sry-type high-mobility group box-9 (Sox9) is a regulatory transcription factor that binds DNA at specific sites within Col2a1, Agc1 and Hapln genes to induce their transcription [4–6].
In diseases such as rheumatoid arthritis and osteoarthritis there is a shift in the equilibrium in cartilage production and degradation towards catabolism. TNFα, a potent inflammatory mediator, is found at higher levels in the synovial fluid bathing articular cartilage in diseased joints compared with that of normal, healthy joints [7–9]. Previous work has shown that treatment of chondrocytes with TNFα downregulates the expression of Col2a1, Agc1 and Hapln1 without inducing apoptosis [10–13]. Furthermore, the activation of NFκB) by TNFα signalling reduces Sox9 activity, possibly through competition for the transcriptional cofactor p300 [10, 12]. Other signalling pathways are known to be activated by TNFα, however, including the extracellular regulated kinase (ERK)/mitogen-activated protein kinase pathway (reviewed in ).
TNFα initiates the activation of ERK/mitogen-activated protein kinase through the adaptor protein, Grb2, binding to the TNFα receptor 1, leading to activation of the ras/mitogen-activated kinase kinase (MEK)/ERK signalling cascade . In immortalized chondrocytes and primary rat chondrocytes, ERK1/2 can be phosphorylated as early as 15 minutes of treatment with TNFα [10, 11]. Inhibition of MEK1/2 signalling can attenuate the decreases in Col2a1, Agc1 and Hapln1, as determined by northern blot analysis [10, 11]. TNFα also regulates the activity of NFκB and Sox9 in chondrocytes [10, 12]. TNFα-induced NFκB DNA binding in immortalized chondrocytes is reduced by inhibition of MEK1/2 signalling . TNFα may therefore regulate the expression of a subset of genes by alterations in the activity of these transcription factors in a MEK1/2-dependent manner.
Although some information is known about selected changes in chondrocyte gene expression in response to TNFα-activated MEK/ERK signalling, the overall impact of this pathway on changes to the chondrocyte gene expression and the downstream transcriptional mechanisms mediating these changes has been poorly defined. We sought to identify the extent to which MEK/ERK may contribute to the overall changes in chondrocyte gene expression in response to TNFα.
In the present study, we found that ERK1/2 undergoes multiple temporal phosphorylation events in response to TNFα-induced MEK1/2 activation. We discovered that approximately 20% of the genes that changed at least 1.45-fold with TNFα were dependent on MEK1/2 activation. A significant subset of these genes encoded proteins that localized to the extracellular space and had collagenase or hyaluronic acid binding activities. We determined that specific matrix metalloproteinases and cartilage-selective ECM transcript levels were regulated by MEK/ERK, while transcripts of the inflammatory gene macrophage colony stimulating factor 1 (Csf-1), were regulated in a MEK1/2-independent manner. Surprisingly, the activation of NFκB and the inhibition of Sox9 activity by TNFα were independent of MEK1/2. The DNA binding activity of the transcription factor early growth response 1 (Egr-1), however, was regulated by TNFα-activated MEK1/2 signalling. Finally, we determined that Egr family members are responsible for the TNFα-induced, MEK-dependent reductions in mRNA transcripts. Egr-1 may therefore regulate a select number of genes in response to TNFα-activated MEK/ERK signalling.
These findings reveal that MEK/ERK-dependent transcription factors that are downstream of TNFα, such as Egr-1, may be targets for therapeutic intervention to treat the pathophysiology of arthritis without disrupting other potential positive effects of TNFα.
Materials and methods
Primary chondrocyte culture
Chondrocytes were isolated from the femoral condyles of neonatal (1 day old) rats as previously described . The cartilage canals in newborn rats do not form in the femoral condyles until 5 days postnatal and radiographic signs of the secondary ossification centre do not appear until about 10 days postnatal . Furthermore, to avoid hypertrophic chondrocytes, the upper two-thirds of the cartilage was taken. Cells were plated onto tissue culture plastic (Falcon, Franklin Lakes, NJ, USA) at a density of ~2.5 × 104 cells/cm2. Under these conditions, the culture consists of an essentially pure chondrocyte population.
Monolayer chondrocyte cultures were grown in RPMI 1640 media (Invitrogen, Burlington, ON, Canada) supplemented with 5% foetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin and 1% HEPES buffer (Invitrogen) until approximately 90% confluence was reached (6 to 7 days). Prior to treatment, chondrocytes were incubated in serum-free media overnight. For inhibitor studies, chondrocytes were pretreated with the selective MEK1/2 inhibitor U0126 (10 μM; Promega, Thermo Fisher Scientific, Rockford, IL, USA)  for 30 minutes. As previously shown, U0126 has very low inhibitory activity towards other protein kinases . Furthermore, previous studies in our laboratory have demonstrated that 24-hour treatment with 10 μM U0126 had no significant effect on the cell morphology or organization in culture . As controls, cultures were treated in parallel with dimethyl sulfoxide (DMSO) (vehicle for inhibitors), U0124 (10 μM; Calbiochem, EMD Biosciences Inc., La Jolla, CA, USA) or the selective epidermal growth factor receptor inhibitor PD153035 (1 μM; Calbiochem, EMD Biosciences Inc.) . Cultures were then treated with human recombinant TNFα (30 ng/ml; Endogen, Thermo Fisher Scientific) for 15 minutes to 24 hours.
Antibodies used in this study included anti-phospho-tyrosine-ERK1/2 (E4), anti-Egr-1 (588), anti-α-tubulin (E-19), and anti-NFκB p65 (C-20) antibodies (all from Santa Cruz Biotechnology, Santa Cruz, CA, USA). Horseradish peroxidase-conjugated goat-anti-rabbit or rabbit-anti goat secondary antibodies were obtained from Thermo Fisher Scientific.
Protein isolation and western blotting
Nuclear and cytoplasmic extracts were isolated using a modified method of Dignam and colleagues , as previously described . Total cell extracts were isolated using RIPA buffer as previously described . Protein concentration was determined using the Pierce BCA Protein assay kit (Pierce, Thermo Fisher Scientific), as per the manufacturers' instructions. For western blotting, 20 μg cytoplasmic protein was loaded into 10% polyacrylamide gels containing SDS and separated by electrophoresis. Proteins were transferred onto Protran™ nitrocellulose membranes (Whatman, Inc., Florham Park, NJ, USA) by electroblotting and were stained with Ponceau S to qualitatively determine equal loading of samples and efficient transfer of proteins. Membranes were blocked in 5% nonfat milk (Carnation, North York, ON, Canada) in 0.05% Tris-buffered saline containing 0.05% Tween-20 (TBST) for 1 hour followed by incubation with primary antibodies in blocking buffer overnight. Membranes were washed in TBST and incubated in 5% milk-TBST with appropriate secondary antibody for 45 minutes to 1.5 hours. Membranes were then washed with TBST and rinsed in Tris-buffered saline prior to incubation in Supersignal West Pico Chemiluminescent Substrate (Pierce, Thermo Fisher Scientific) and exposed to Amersham Hyperfilm ECL (GE Healthcare Bio-Sciences Inc., Baie d'Urfé, QC, Canada). Membranes were stripped using 1 M glycine, pH 2.5, and washed using TBST prior to reprobing.
Total RNA was isolated from cultures by Trizol (Invitrogen) followed by RNeasy clean-up (Qiagen, Mississauga, ON, Canada) as per the manufacturer's directions. Total RNA was quantified spectrophotometrically. High-quality RNA for use in the microarray analysis was confirmed by analysis in the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA).
Total mRNA (10 μg) from two biological replicates of cells treated with DMSO, U0126, TNFα or U0126 and TNFα, were amplified once and hybridized to RAT230_2.0 gene chips (Affymetrix, Santa Clara, CA, USA). Amplification, labelling, hybridization and detection were performed at the London Regional Genomics Centre (London, ON, Canada) according to the manufacturers' instructions.
Microarray data and gene ontology analysis
The raw expression values were imported into Genespring GX 7.3 (Agilent Technologies). Raw expression values <0.01 were set to 0.01 and the normalization per chip was set to the 50th percentile. Relative gene expression of the 31,099 probe sets on the chip was determined by normalizing the raw expression values for each probe set to the DMSO control (= one-fold change for each probe set) from each independent experiment. To identify genes that were TNFα-regulated, probe sets that were altered ≥ 1.45 in DMSO/TNFα-treated cultures compared with DMSO-treated cultures were determined for each independent experiment. Probe sets identified as being TNFα regulated in both independent experiments were selected for further analysis. Genes whose transcript levels changed ≥ 1.45-fold were selected for study, as our microarray analysis revealed that aggrecan mRNA – a transcript previously shown to be TNFα sensitive  – was reduced approximately 1.45-fold and thus served as a positive control establishing the validity of our microarray data.
To identify probe sets whose changes were altered by TNFα in a MEK1/2-dependent fashion, we normalized the fold change in gene expression of U0126/TNFα-treated cultures to that of cultures treated with U0126 alone from both independent experiments. We determined probe sets that were altered <1.45-fold in response to DMSO/TNFα treatment, and hence were TNFα regulated in a U0126-sensitive fashion. The remainder of the genes on the lists of TNFα-regulated probe sets were determined to be TNFα regulated and MEK independent. Probe sets identified as being TNFα regulated and MEK/ERK dependent or MEK/ERK independent in both independent experiments were selected for further analysis.
Genes were also identified whose basal expression was sensitive to U0126 alone. Probe sets altered ≥ 1.45-fold in response to U0126 treatment relative to DMSO treatment were identified in both independent experiments. The limited number of genes that were altered with U0126 in both experiments (89/31,099) prevented the use of meaningful cluster analysis, but nonetheless served as a potent indication of the selectivity of the U0126 inhibitor. The generated list was then compared with the list of genes changing ≥ 1.45-fold with DMSO/TNFα to identify genes that were basal TNFα independent but MEK/ERK dependent and those genes that were both TNFα and basal MEK/ERK dependent.
The fold change in the transcript levels increased or decreased ≥ 1.45-fold in both independent experiments was averaged. The generated lists of genes determined as TNFα-activated MEK/ERK dependent and TNFα-activated MEK/ERK independent were analysed using the gene ontology browser in Genespring GX 7.3. Major cellular components and molecular functions subcategories of protein products from the list of genes were identified. The resulting list of cellular component ontologies was filtered such that a minimum of 10 genes must be in the initial group of annotated genes from the microarray and the resulting subcategory must be significantly represented (P < 0.05). Selected genes within the extracellular space ontology were then organized into subcategories that were significantly represented by the molecular function ontologies (P < 0.01).
Quantitative real-time PCR
Total RNA (25 ng) was amplified using the TaqMan One Step RT-PCR Master Mix (4309169; Applied Biosystems Inc., Streetsville, ON, Canada). Primer/probe sets to rat type II collagen (Col2a1, Rn00564954_m1), aggrecan 1 (Agc1, Rn00573424_m1), link protein (Hapln1, Rn00569884_m1), matrix metalloproteinase-9 (Mmp-9, Rn00579162_m1), matrix metalloproteinase-12 (Mmp-12, Rn00588640_m1), macrophage Csf-1 (Csf-1, Rn00576849_m1) and eukaryotic 18S rRNA (4352930E) were used to analyse relative transcript levels.
Reverse transcription and quantitative real-time PCR reactions were performed using the Prism 7900 HT Sequence Detector (Applied Biosystems Inc.). Samples were incubated at 48°C for 30 minutes to make cDNA templates. The resulting cDNA was amplified for 40 cycles. Cycles alternated between 95°C for 15 seconds and 60°C for 1 minute.
Results were analysed using SDS v2.1 software (Applied Biosystems Inc.). The ΔΔCt method was used to calculate gene expression levels relative to 18S and normalized to vehicle-treated cells. Data were log-transformed prior to analysis by one-way analysis of variance and Tukey's post-hoc test, paired t tests and Student's t tests, using Graphpad Software v. 4 (Graphpad Software, La Jolla, CA, USA).
Confluent cell cultures were detached using trypsin-ethylenediamine tetraacetic acid (Invitrogen), pelleted, and resuspended in serum-free culture medium. Cells were then plated into 48-well dishes (3.4 × 104 cells/well) in 200 μl and were transfected with equal amounts of reporter plasmids. The reporter plasmids used in this study included the κB reporter (BD Biosciences, Mississauga, ON, Canada), comprising four tandem repeats of the κB response element upstream of the firefly luciferase reporter sequence and a type II collagen enhancer luciferase reporter (Sox9 reporter) containing four repeats of the 48-base-pair minimal enhancer of the type II collagen gene (pGL3 (4 × 48)) . Each minimal enhancer sequence contains a binding site for Sox9. Multiple repeats of the minimal enhancer are required for optimal firefly luciferase expression . Cells were transfected with 20 μl serum-free media containing the equivalent of 0.156 μg Sox9 reporter or NFκB reporter and 0.352 μl Fugene 6 transfection reagent (Roche Diagnostics Corporation, Indianapolis, IN, USA). In all experiments, chondrocytes were co-transfected with a 0.002 μg renilla luciferase plasmid (pRL-CMV; Thermo Fisher Scientific) to control for transfection efficiency. Cultures were transfected for 4 hours prior to addition of 200 μl foetal bovine serum containing media.
After overnight incubation, the media was aspirated off from the transfected cultures and replaced with serum-free media. Cultures were treated as indicated above and collected using Passive Lysis Buffer (Thermo Fisher Scientific) as directed by the manufacturer. Luciferase activity was measured using the Dual Luciferase Assay System (Thermo Fisher Scientific) in an L-max II microplate reader (Molecular Devices, Sunnyvale, CA, USA). Tanscription-factor-regulated firefly luciferase units were adjusted relative to constitutive cytomegalovirus-regulated renilla luciferase units obtained in control DMSO-treated, U0124-treated or U0126-treated cultures. Data were log-transformed prior to analysis by Student's t tests and one-way analysis of variance using Graphpad Software v. 4 (Graphpad Software).
Electrophoretic mobility shift assays
Binding of nuclear protein complexes to the κB or Egr-1 cognate elements was determined as previously described [10, 12]. The double-stranded oligodeoxynucleotides (ODNs) containing the κB cognate sequence (5'-AGTTGAGGGGACTTTCCCAGG-3'), the Egr cognate sequence (5'-GGATCCAGCGGGGGCGAGCGGGGGCGA-3') and the Egr mutant sequence (5'-GGATCCAGCTAGGGCGAGCTAGGGCGA-3') were purchased from Santa Cruz Biotechnology. Competition assays were performed by adding 100-fold molar excess of unlabelled probe to the nuclear extract-labelled probe mixture. Antibody interference assays were performed by adding 2 μg antibody against Egr-1 (specific) or NFκB (nonspecific) 1 hour prior to the addition of nuclear extract to the buffered radiolabelled DNA. Samples were loaded into 4% polyacrylamide gels and were electrophoresed for 3.5 hours. Following electrophoresis, gels were dried and exposed to Amersham Hyperfilm-MP (GE Healthcare Bio-Sciences Inc.) at -80°C.
Promoter analysis for putative transcription factor binding sites
Upstream regions proximal to the transcriptional start site of the rat Col2a1 and Agc1 genes have been described previously [24, 25]. Upstream regions from the transcriptional start site (~5,000 base pairs) of the Rattus Norvegicus Col2a1 [GenBank:NM_012929.1] and Agc1 [GenBank:NM_022190] genes were obtained and analysed for putative transcription factor binding sites by TRANSFAC analysis .
Oligodeoxynucleotide decoy assay
Chondrocytes were plated at 1.2 × 106 cells/well in six-well culture dishes. Single stranded, phosphorothiol-modified ODNs were annealed by heating complementary ODNs to 98°C for 20 minutes followed by cooling to room temperature for 3 to 4 hours. Chondrocytes were transfected with 2 μM double-stranded ODNs corresponding to the cognate EGR-1 binding sequence (5'-ggaTCCAGCGGGGGCGAGCGGGGgcgA-3') or the Egr mutant sequence (5'-ggaTCCAGCTAGGGCGAGCTAGGgcgA-3'; Sigma Genosys, Oakville, ON, CA) using 1% HiPerfect transfection reagent (Qiagen), as per the manufacturer's instructions. (Lowercase letters indicate phosphorothiol-modified bases.)
To optimize double-stranded ODN transfection conditions, chondrocytes were transfected cells with increasing concentrations of double-stranded, fluorescein-tagged and phosphorothiol-modified ODNs, and the cells were imaged by live-cell fluorescent microscopy (data not shown). Chondrocytes were allowed to grow for 24 hours in the presence of ODNs, after which cells were washed and cultured in serum-free RPMI media overnight. Chondrocytes were treated with TNFα for 24 hours, as described, and total RNA was collected for analysis by real-time PCR.
ERK1/2 is phosphorylated by TNFα in chondrocytes
U0126 blocks part of the TNFα-dependent gene expression changes in chondrocytes
To investigate the global impact of U0126 on TNFα-modulated gene expression in chondrocytes, we utilized microarrays to analyse changes in chondrocyte mRNA expression. Cells were serum-starved overnight and were treated with or without U0126 (10 μM, 30 min) prior to addition of TNFα for 24 hours. Cells were treated with TNFα for 24 hours as previous data showed that this length of TNFα treatment was necessary to generate a TNFα-mediated suppression of chondrocyte matrix genes, owing to the stability of chondrocyte matrix gene mRNAs [27–30].
Selective extracellular matrix and proteinase genes are regulated by TNFα-induced MEK/ERK signalling
Extracellular space genes regulated at least 1.45-fold by TNFαa
Basal MEK/ERK dependent
TNF + U0126
TNFα-regulated MEK/ERK dependent
Hyaluronic acid binding activity
Hyaluronan and proteoglycan link protein 1
Collagenase or metallopeptidase activity
Matrix metallopeptidase 12
Matrix metallopeptidase 9
Arts1, ERAP1, Appils
Type 1 TNF receptor shedding aminopeptidase regulator
Complement component 4 binding protein, alpha
Adhesion molecule with Ig-like domain 2
Calcium channel, voltage-dependent, α2/δ3 subunit
Cell growth regulator with EF hand domain 1
Cytochrome P450, family 4, subfamily b, polypeptide 1
Gm1960, Cinc2, Cinc-2
Gene model 1960 (NCBI)
TNFα-regulated MEK/ERK independent
A disintegrin and metalloproteinase domain 17 (TNF, alpha, converting enzyme)
Matrix metallopeptidase 13
Serine (or cysteine) proteinase inhibitor, clade B, member 2
Plat, tPA, PATISS
Plasminogen activator, tissue
Plasminogen activator, urokinase
Complement component 1, s subcomponent
Carboxypeptidase × 1 (M14 family) (predicted)
Matrix metallopeptidase 3
Ccl5, Scya5, Rantes
Chemokine (C-C motif) ligand 5
[GenBank:NM_001033882], [GenBank:NM_001033883], [GenBank:NM_022177]
Chemokine (C-X-C motif) ligand 12
Ccl20, ST38, Scya20
Chemokine (C-C motif) ligand 20
Cx3cl1, Cx3c, Scyd1
Chemokine (C-X3-C motif) ligand 1
Cxcl1, Gro1, CINC-1
Chemokine (C-X-C motif) ligand 1
Cxcl10, IP-10, Scyb10
Chemokine (C-X-C motif) ligand 10
Ccl2, MCP-1, Scya2, Sigje
Chemokine (C-C motif) ligand 2
Cytokine or growth factor activity
Bone morphogenetic protein 2
Growth differentiation factor 10
Macrophage colony-stimulating factor 1
IFNγ receptor 1
Secreted phosphoprotein 1
Vascular endothelial growth factor A
Tap1, Cim, Abcb2
Transporter 1, ATP-binding cassette, subfamily B (MDR/TAP)
Tap2, Cim, Abcb3
Transporter 2, ATP-binding cassette, subfamily B (MDR/TAP)
G-protein coupled receptor binding
Receptor (calcitonin) activity modifying protein 1
Receptor (calcitonin) activity modifying protein 2
Regulation of Sox9 and NFκB activity by TNFα are independent of MEK/ERK signalling
Egr-1 DNA binding is increased in a TNFα-induced MEK/ERK-dependent manner
To determine additional, candidate transcription factors that may regulated by MEK/ERK, we considered that Egr-1 is a known early target of MEK/ERK signalling and that IL-1 induction of Egr-1 inhibits the activity of the human type II collagen proximal promoter . We therefore focused the remainder of our study on Egr-1 and its possible role in regulating U0126-sensitive TNFα-induced genes.
Egr family DNA binding is responsible for decreased chondrocyte matrix gene expression
In the present study, we used the MEK1/2 inhibitor U0126 to identify the possible contribution of the MEK/ERK signalling pathway to changes in chondrocyte gene expression in response to TNFα. Inspection of the ~20% of TNFα-regulated chondrocyte mRNAs whose expression was modulated by MEK1/2 revealed a significant representation of genes whose protein products localized to the extracellular space, and had proteinase activity (for example, Mmp-9 and Mmp-12, which were induced by TNFα) or hyaluronic acid binding activity (for example, the matrix-associated genes Agc1 and Hapln1, which were suppressed by TNFα). Mmp-9 and Mmp-12 cleave selective proteoglycans and collagens [32–34] while Mmp-9 is also an important mediator of inflammatory arthritis . Furthermore, we have shown that increases in transcripts encoding proinflammatory genes, such as macrophage Csf-1, were U0126 insensitive. Collectively these results suggest the intriguing notion that, compared with the TNFα-regulated transcript levels of genes involved in inflammation, TNFα-induced matrix catabolism may selectively require MEK/ERK. Further efforts will be required to assess whether similar mechanisms might operate in adult rat or human chondrocytes, or in cells isolated from patients with arthritis. Nonetheless, our data – for the first time – suggest that MEK inhibitors modify the excessive matrix degradation in arthritis.
Consistent with TNFα-induced increases in macrophage Csf-1 transcript levels observed in this study, macrophage Csf-1 protein levels are also induced by TNFα in chondrocytes . In rat articular chondrocytes, macrophage Csf-1-induced signalling increases its own expression and the expression of the matricellular protein CCN2 (formerly known as connective tissue growth factor) . CCN2 is required for Col2a1 and Agc1 expression in mouse chondrocytes  yet does not result in hypertrophic differentiation of rat articular chondrocytes . Taken together, inhibition of TNFα-induced MEK/ERK or downstream transcription factors may rescue cartilage ECM gene expression and promote articular cartilage regeneration through continued macrophage Csf-1 expression.
In immortalized chondrocytes, NFκB-DNA binding activity is dependent on TNFα-induced MEK/ERK signalling , consistent with studies in other immortalized cells such as B-cell lymphoma cell lines . In our present study using primary chondroctyes, however, both TNFα-regulated NFκB reporter activity and NFκB-DNA binding were unaltered by MEK/ERK inhibition. Immortalized cells may therefore have altered signalling that activates NFκB in a MEK/ERK-dependent manner by TNFα. Furthermore, we showed that pretreatment of primary chondrocytes with DMSO or DMSO-soluble inhibitors, such as U0124, U0126 and PD153035, reduced TNFα-activated NFκB-DNA binding activity. The regulation of NFκB-DNA binding in primary cells can therefore be explained by the nonspecific effect of DMSO on NFκB activation.
In the present study we determined that, in addition to NFκB, TNFα-regulated reductions in Sox9 activity were also independent of MEK/ERK signalling. Previous studies from our laboratory have shown that reductions in Sox9 activity by TNFα are dependent on NFκB nuclear translocation [10, 12], a mechanism probably involving reductions in p300 histone acetylase activity associated with Sox9 . MEK/ERK-independent reductions in Sox9 activity could therefore explain the inability of U0126 to completely reverse the TNFα-induced reductions in cartilage ECM gene transcript levels observed in this study.
We showed that Egr-1 DNA binding was increased by TNFα in a U0126-sensitive fashion. Moreover, competitive inhibition of Egr-1 binding to genomic targets attenuated decreases in cartilage ECM genes in response to TNFα. These results suggest that TNFα can modify gene expression in chondrocytes via MEK/ERK through the induction of Egr-1 DNA binding activity. Treatment of chondrocytes with IL-1 increases the Egr-1 protein and DNA binding, leading to decreased human type II collagen promoter activity through competition of Egr-1 for the Sp1 binding sites . Previous studies have also identified that there are putative Sp1 binding sites in the aggrecan promoter of the chick, mouse and rat [25, 41]. In this study, we identified putative overlapping binding sites for Sp1 and Egr-1 in both the rat COL2A1 and AGC1 promoters proximal to the transcriptional start site. Although beyond the scope of our current report, Col2a1 and Agc1 transcription are probably regulated by inhibitory actions of Egr-1 in competition for Sp1 binding sites. Collectively, these data suggest that, in chondrocytes, alterations in Egr-1 DNA binding activity by TNFα-induced MEK/ERK signalling is necessary for the transcriptional regulation of downstream cartilage ECM genes.
In the current study, pharmacological inhibition of MEK resulted in significant attenuation of the TNFα-induced decreases to Col2a1, Agc1 and Hapln1 24 hours post treatment. Depending on the species the half-life of Col2a1 mRNA in chondrocytes is between 15 and 18 hours [27, 29, 30], whereas the half-life of Agc1 mRNA is about 4 hours in bovine articular chondrocytes . In this study we observed ~50% reduction in Col2a1 and ~70% reduction in Agc1 transcript levels after 24 hours. Previous studies from our laboratory have indicated that inhibition of Col2a1 transcripts in response to TNFα results from an inhibition of transcription and not from changes to message stability . Furthermore, treatment of chondrocytes with actinomycin D, a transcription inhibitor, decreased Col2a1 and Agc1 mRNAs to a level comparable with that of TNFα treatment alone (unpublished data). Collectively, TNFα-induced reductions in cartilage ECM transcripts in this study are consistent with regulation of these mRNAs through inhibition of transcription. Although it is possible that TNFα may modulate cartilage ECM transcript expression in an indirect fashion, the relatively delayed kinetics of TNFα-modulated cartilage ECM transcripts is probably due to the stability of the mRNAs.
Most therapies for rheumatoid arthritis, specifically biologics, are targeted towards TNFα protein and not towards its activated signalling pathways . Targeted therapies that block specific subcellular molecules involved in TNFα-activated signalling pathways, however, may be useful in selectively modifying chondrocyte responses to TNFα. Our data suggest that MEK/ERK may selectively be required for TNFα-modulated proteinase and cartilage ECM transcripts, but not for inflammatory gene transcripts. These results raise the intriguing notion that MEK/ERK inhibitors might be used to block the ability of TNFα to promote matrix catabolism but leave perhaps more beneficial effects of TNFα unaltered. In the long term, our observations may be of relevance for developing new methods of treating arthritis. In particular, antagonizing MEK/ERK or activating Egr-1 may be useful methodologies for reversing cartilage degradation observed in both osteoarthritis and rheumatoid arthritis.
type II collagen (α)
colony stimulating factor 1
early growth response
extracellular regulated kinase
mitogen-activated kinase kinase
polymerase chain reaction
Sry-type high-mobility group box
Tris-buffered saline with Tween-20
tumour necrosis factor.
The present study was supported by operating grants 14095 and 81243 (to SMB and AL) from the Canadian Institutes of Health Research. JSR is a recipient of a PGS D scholarship from the Natural Sciences and Engineering Research Council. The authors thank David Carter at the London Regional Genomic Centre for his help with the microarray analysis.
- Eyre D: Collagen of articular cartilage. Arthritis Res. 2002, 4: 30-35. 10.1186/ar380.PubMed CentralView ArticlePubMedGoogle Scholar
- Kiani C, Chen L, Wu YJ, Yee AJ, Yang BB: Structure and function of aggrecan. Cell Res. 2002, 12: 19-32. 10.1038/sj.cr.7290106.View ArticlePubMedGoogle Scholar
- Morgelin M, Heinegard D, Engel J, Paulsson M: The cartilage proteoglycan aggregate: assembly through combined protein-carbohydrate and protein-protein interactions. Biophys Chem. 1994, 50: 113-128. 10.1016/0301-4622(94)85024-0.View ArticlePubMedGoogle Scholar
- Bell DM, Leung KK, Wheatley SC, Ng LJ, Zhou S, Ling KW, Sham MH, Koopman P, Tam PP, Cheah KS: SOX9 directly regulates the type-II collagen gene. Nat Genet. 1997, 16: 174-178. 10.1038/ng0697-174.View ArticlePubMedGoogle Scholar
- Kou I, Ikegawa S: SOX9-dependent and -independent transcriptional regulation of human cartilage link protein. J Biol Chem. 2004, 279: 50942-50948. 10.1074/jbc.M406786200.View ArticlePubMedGoogle Scholar
- Sekiya I, Tsuji K, Koopman P, Watanabe H, Yamada Y, Shinomiya K, Nifuji A, Noda M: SOX9 enhances aggrecan gene promoter/enhancer activity and is up-regulated by retinoic acid in a cartilage-derived cell line, TC6. J Biol Chem. 2000, 275: 10738-10744. 10.1074/jbc.275.15.10738.View ArticlePubMedGoogle Scholar
- Chu CQ, Field M, Feldmann M, Maini RN: Localization of tumor necrosis factor a in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. 1991, 34: 1125-1132. 10.1002/art.1780340908.View ArticlePubMedGoogle Scholar
- Kammermann JR, Kincaid SA, Rumph PF, Baird DK, Visco DM: Tumor necrosis factor α (TNFα) in canine osteoarthritis: immunolocalization of TNF-α, stromelysin and TNF receptors in canine osteoarthritic cartilage. Osteoarthr Cartil. 1996, 4: 23-34. 10.1016/S1063-4584(96)80004-5.View ArticlePubMedGoogle Scholar
- Smith MD, Triantafillou S, Parker A, Youssef PP, Coleman M: Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol. 1997, 24: 365-371.PubMedGoogle Scholar
- Séguin CA, Bernier SM: TNFα suppresses link protein and type II collagen expression in chondrocytes: role of MEK1/2 and NFkB signaling pathways. J Cell Physiol. 2003, 197: 356-369. 10.1002/jcp.10371.View ArticlePubMedGoogle Scholar
- Klooster AR, Bernier SM: Tumor necrosis factor α and epidermal growth factor act additively to inhibit matrix gene expression by chondrocyte. Arthritis Res Ther. 2005, 7: R127-R138. 10.1186/ar1464.PubMed CentralView ArticlePubMedGoogle Scholar
- Rockel JS, Kudirka JC, Guzi AJ, Bernier SM: Regulation of Sox9 activity by crosstalk with nuclear factor-κB and retinoic acid receptors. Arthritis Res Ther. 2008, 10: R3-10.1186/ar2349.PubMed CentralView ArticlePubMedGoogle Scholar
- Carames B, Lopez-Armada MJ, Cillero-Pastor B, Lires-Dean M, Vaamonde C, Galdo F, Blanco FJ: Differential effects of tumor necrosis factor-alpha and interleukin-1beta on cell death in human articular chondrocytes. Osteoarthr Cartil. 2008, 16: 715-722. 10.1016/j.joca.2007.10.006.View ArticlePubMedGoogle Scholar
- MacEwan DJ: TNF receptor subtype signalling: differences and cellular consequences. Cell Signal. 2002, 14: 477-492. 10.1016/S0898-6568(01)00262-5.View ArticlePubMedGoogle Scholar
- Hildt E, Oess S: Identification of Grb2 as a novel binding partner of tumor necrosis factor (TNF) receptor I. J Exp Med. 1999, 189: 1707-1714. 10.1084/jem.189.11.1707.PubMed CentralView ArticlePubMedGoogle Scholar
- Hedberg A, Messner K, Persliden J, Hildebrand C: Transient local presence of nerve fibers at onset of secondary ossification in the rat knee joint. Anat Embryol (Berl). 1995, 192: 247-255.View ArticleGoogle Scholar
- Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magolda RL, Scherle PA, Trzaskos JM: Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem. 1998, 273: 18623-18632. 10.1074/jbc.273.29.18623.View ArticlePubMedGoogle Scholar
- Davies SP, Reddy H, Caivano M, Cohen P: Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000, 351: 95-105. 10.1042/0264-6021:3510095.PubMed CentralView ArticlePubMedGoogle Scholar
- Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, Leopold WR, Connors RW, Bridges AJ: A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science. 1994, 265: 1093-1095. 10.1126/science.8066447.View ArticlePubMedGoogle Scholar
- Dignam JD, Lebovitz RM, Roeder RG: Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 1983, 11: 1475-1489. 10.1093/nar/11.5.1475.PubMed CentralView ArticlePubMedGoogle Scholar
- Kudirka JC, Panupinthu N, Tesseyman MA, Dixon SJ, Bernier SM: P2Y nucleotide receptor signaling through MAPK/ERK is regulated by extracellular matrix: involvement of β 3 integrins. J Cell Physiol. 2007, 213: 54-64. 10.1002/jcp.21087.View ArticlePubMedGoogle Scholar
- Weston AD, Chandraratna RA, Torchia J, Underhill TM: Requirement for RAR-mediated gene repression in skeletal progenitor differentiation. J Cell Biol. 2002, 158: 39-51. 10.1083/jcb.200112029.PubMed CentralView ArticlePubMedGoogle Scholar
- Lefebvre V, Zhou G, Mukhopadhyay K, Smith CN, Zhang Z, Eberspaecher H, Zhou X, Sinha S, Maity SN, de Crombrugghe B: An 18-base-pair sequence in the mouse proa1(II) collagen gene is sufficient for expression in cartilage and binds nuclear proteins that are selectively expressed in chondrocytes. Mol Cell Biol. 1996, 16: 4512-4523.PubMed CentralView ArticlePubMedGoogle Scholar
- Kohno K, Sullivan M, Yamada Y: Structure of the promoter of the rat type II procollagen gene. J Biol Chem. 1985, 260: 4441-4447.PubMedGoogle Scholar
- Watanabe H, Gao L, Sugiyama S, Doege K, Kimata K, Yamada Y: Mouse aggrecan, a large cartilage proteoglycan: protein sequence, gene structure and promoter sequence. Biochem J. 1995, 308 (Pt 2): 433-440.PubMed CentralView ArticlePubMedGoogle Scholar
- Matys V, Kel-Margoulis OV, Fricke E, Liebich I, Land S, Barre-Dirrie A, Reuter I, Chekmenev D, Krull M, Hornischer K, Voss N, Stegmaier P, Lewicki-Potapov B, Saxel H, Kel AE, Wingender E: TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes. Nucleic Acids Res. 2006, 34: D108-D110. 10.1093/nar/gkj143.PubMed CentralView ArticlePubMedGoogle Scholar
- Askew GR, Wang S, Lukens LN: Different levels of regulation accomplish the switch from type II to type I collagen gene expression in 5-bromo-2' -deoxyuridine-treated chondrocytes. J Biol Chem. 1991, 266: 16834-16841.PubMedGoogle Scholar
- Curtis AJ, Devenish RJ, Handley CJ: Modulation of aggrecan and link-protein synthesis in articular cartilage. Biochem J. 1992, 288 (Pt 3): 721-726.PubMed CentralView ArticlePubMedGoogle Scholar
- Galera P, Redini F, Vivien D, Bonaventure J, Penfornis H, Loyau G, Pujol JP: Effect of transforming growth factor-β1 (TGF-β1) on matrix synthesis by monolayer cultures of rabbit articular chondrocytes during the dedifferentiation process. Exp Cell Res. 1992, 200: 379-392. 10.1016/0014-4827(92)90186-C.View ArticlePubMedGoogle Scholar
- Goldring MB, Fukuo K, Birkhead JR, Dudek E, Sandell LJ: Transcriptional suppression by interleukin-1 and interferon-gamma of type II collagen gene expression in human chondrocytes. J Cell Biochem. 1994, 54: 85-99. 10.1002/jcb.240540110.View ArticlePubMedGoogle Scholar
- Tan L, Peng H, Osaki M, Choy BK, Auron PE, Sandell LJ, Goldring MB: Egr-1 mediates transcriptional repression of COL2A1 promoter activity by interleukin-1β. J Biol Chem. 2003, 278: 17688-17700. 10.1074/jbc.M301676200.View ArticlePubMedGoogle Scholar
- Fosang AJ, Neame PJ, Last K, Hardingham TE, Murphy G, Hamilton JA: The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B. J Biol Chem. 1992, 267: 19470-19474.PubMedGoogle Scholar
- Gronski TJ, Martin RL, Kobayashi DK, Walsh BC, Holman MC, Huber M, Van Wart HE, Shapiro SD: Hydrolysis of a broad spectrum of extracellular matrix proteins by human macrophage elastase. J Biol Chem. 1997, 272: 12189-12194. 10.1074/jbc.272.18.12189.View ArticlePubMedGoogle Scholar
- Chandler S, Cossins J, Lury J, Wells G: Macrophage metalloelastase degrades matrix and myelin proteins and processes a tumour necrosis factor-α fusion protein. Biochem Biophys Res Commun. 1996, 228: 421-429. 10.1006/bbrc.1996.1677.View ArticlePubMedGoogle Scholar
- Itoh T, Matsuda H, Tanioka M, Kuwabara K, Itohara S, Suzuki R: The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. J Immunol. 2002, 169: 2643-2647.View ArticlePubMedGoogle Scholar
- Campbell IK, Ianches G, Hamilton JA: Production of macrophage colony-stimulating factor (M-CSF) by human articular cartilage and chondrocytes. Modulation by interleukin-1 and tumor necrosis factor α. Biochim Biophys Acta. 1993, 1182: 57-63.View ArticlePubMedGoogle Scholar
- Nakao K, Kubota S, Doi H, Eguchi T, Oka M, Fujisawa T, Nishida T, Takigawa M: Collaborative action of M-CSF and CTGF/CCN2 in articular chondrocytes: possible regenerative roles in articular cartilage metabolism. Bone. 2005, 36: 884-892. 10.1016/j.bone.2004.10.015.View ArticlePubMedGoogle Scholar
- Nishida T, Kawaki H, Baxter RM, Deyoung RA, Takigawa M, Lyons KM: CCN2 (connective tissue growth factor) is essential for extracellular matrix production and integrin signaling in chondrocytes. J Cell Commun Signal. 2007, 1: 45-58. 10.1007/s12079-007-0005-z.PubMed CentralView ArticlePubMedGoogle Scholar
- Nishida T, Kubota S, Nakanishi T, Kuboki T, Yosimichi G, Kondo S, Takigawa M: CTGF/Hcs24, a hypertrophic chondrocyte-specific gene product, stimulates proliferation and differentiation, but not hypertrophy of cultured articular chondrocytes. J Cell Physiol. 2002, 192: 55-63. 10.1002/jcp.10113.View ArticlePubMedGoogle Scholar
- Kurland JF, Voehringer DW, Meyn RE: The MEK/ERK pathway acts upstream of NFkB1 (p50) homodimer activity and Bcl-2 expression in a murine B-cell lymphoma cell line. MEK inhibition restores radiation-induced apoptosis. J Biol Chem. 2003, 278: 32465-32470. 10.1074/jbc.M212919200.View ArticlePubMedGoogle Scholar
- Pirok EW, Li H, Mensch JR, Henry J, Schwartz NB: Structural and functional analysis of the chick chondroitin sulfate proteoglycan (aggrecan) promoter and enhancer region. J Biol Chem. 1997, 272: 11566-11574. 10.1074/jbc.272.17.11566.View ArticlePubMedGoogle Scholar
- Lorenz HM, Kalden JR: Perspectives for TNF-α-targeting therapies. Arthritis Res. 2002, 4 (Suppl 3): S17-S24. 10.1186/ar564.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.